The present invention relates to peptides capable of forming a gel and to their use in tissue engineering and bioprinting. The present invention furthermore relates to a gel comprising a peptide in accordance with the present invention, to a method of preparing such gel and to the use of such gel. In one embodiment, such gel is a hydrogel. The present invention furthermore relates to a wound dressing or wound healing agent comprising a gel according to the present invention and to a surgical implant or stent comprising a peptide scaffold formed by a gel according to the present invention. Moreover, the present invention also relates to a pharmaceutical and/or cosmetic composition, to a biomedical device or an electronic device comprising the peptide according to the present invention.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation.

Disclosed herein are a biodegradable polymer microparticle for a filler comprising a core and a shell, wherein the core contains secondary particles including aggregates of a plurality of primary particles, the shell has a raspberry shaped structure, an average particle diameter (D.sub.50) of the biodegradable polymer microparticle ranges from 20 to 200 μm, a manufacturing method thereof, a freeze-dried body including the same, and filler injection including the same.

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.

A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-mat rix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent. Methods of making and using the pre-matrix composition and the device are also provided.

The invention relates to beads and a composition comprising an aqueous phase comprising a plurality of beads, the beads comprising or consisting in a hydrogel matrix comprising at least one carboxyalkyl chitosan having glucosamine units, N-acetyl-glucosamine units and glucosamine units substituted with a carboxyalkyl group, the carboxyalkyl chitosan being crosslinked by covalent bonds between the carboxyalkyl chitosan chains and/or co-crosslinked by covalent bonds with one or more other polymers.

The invention also relates to processes for their preparation and applications thereof.

Described herein are regenerative approaches with tunable cell-cell and cell-matrix interactions to enhance the ability to regenerate multiple zones within a construct with each zone possessing a unique, optimum, level of cell-cell and cell-matrix interaction.

The chemically cross-linked hydrogel is a hydrogel formed by reaction of silk with a crosslinking agent, and the crosslinking agent is a diglycidyl ether crosslinking agent. The hydrogel is obtained by dissolving silk fibers in a lithium bromide solution and crosslinking through the crosslinking agent. The hydrogel has good elasticity, and can recover more than 90% of its volume/height after being compressed for 100 cycles with a compressive deformation of 20%. The silk is very stable in matrix structure and mechanical properties. After incubation in PBS at 37° C. for 30 days, the content of β-sheets in the secondary structure elements of the silk is less than or equal to 40%, and its compressive modulus is less than or equal to 100% (with a compressive deformation of 20%). The hydrogel has good biocompatibility and adjustable biodegradability, and can be used for repairing or filling tissues in subjects.

This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.